Stem cell patent wars
Re: "End this Stem Cell Racket"
References1. R. Gallagher, "End this stem cell racket," The Scientist, 20(11):13, November 2006. 2. G. McGee, "Working with stem cells? Pay up," The Scientist, 20(11):24, November 2006. 3. K.S. Taymor, et al., "The paths around stem cell intellectual property," Nat Biotechnol, 24:411-3, 2006.
The elite HIV controllers
While briefly dealt with in a piece of otherwise comprehensive reporting,1 the notion of HIV eradication is a bit of a red herring - and has been ever since Diamond's David Ho stood in front of the world (10 years ago this year) and tantalized the world (not to mention thousands of HIV+ individuals desperate to rid their bodies of the infection) with its prospect.
The whole point of PCATs and this terrible new term, "elite controllers," is that host factors (HLA types and immune activation among others) turn out to be more important than viral ones. (It is interesting that no mention was made in the article about SIV infected sooty mangabeys and other primates who live normal lives with normal immune systems even though they are infected with the simian equivalent of HIV.) The Typhoid Mary scenario, alluded to albeit only half seriously, it seems, in your piece, would appear unlikely in that research has already shown that HIV is transmitted only at considerably high levels of plasma viral load.
Teasing out the various immune responses that defang HIV is the most important research effort going on today. Deeks, Lederman, Walker and their colleagues are to be commended for their persistence and ingenuity in pursuing this line of research in a field otherwise suffocated by the mindless development of the next "new and improved" (and at twice the price) antiviral drugs du jour.
Getting Gates funding
Re: Getting your Gates.1 The non-profit sector, especially Gates-funded product development partnerships, are playing an increasingly powerful role in drug development, including with small, innovative companies. This is also true in the area of diagnostics. The Foundation for Innovative New Diagnostics (FIND), has moved with Gates funding to accelerate the development, evaluation, or use of improved diagnostics for infectious diseases in developing countries. Financial support from FIND, along with a clear understanding of developing world markets, makes feasible the development of innovative products that may have looked financially marginal. At the same time, novel intellectual property management and costing strategies ensure the affordability of the products for impoverished sectors of society in disease endemic countries.
Mark Perkins, CSO
FIND, Cointrin, Switzerland
1. J. Yajnik, "Getting your Gates," The Scientist, 20(11):71-3, November 2006.
An article in our November 2006 issue (20:71-3) on non-profit foundation funding for biotech companies misidentified the organism responsible for gonorrhea as a virus. Neisseria gonorrhoeae is, of course, a bacterium. The Scientist regrets the error.